Fewer than a tenth of people that would benefit from GLP-1 drugs including Wegovy are able to get them, warns the WHO as it releases its initial guidance on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging more widespread and fairer access to these injectable treatments.
Based on projections, more than two billion could be obese by 2030 unless action is taken.
"The latest guidelines affirms that obesity is a chronic disease that can be treated with comprehensive and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are significant hurdles to broad availability to the treatments that can aid individuals in losing substantial weight, explains the body.
Weight-Loss Drug Supply Crisis
Even in the present best projected outlook, the manufacturing of such drugs might only reach approximately 100 million people – fewer than 10% of eligible patients, according to the health organization.
The advice encourages governments and firms to widen availability, via strategies like voluntary licensing.
A patent on the active ingredient – the main component of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.
How Obesity Drugs Function
The injections replicate a natural hormone to slow digestion, suppress the appetite and enhance feelings of fullness so people reduce food intake.
People usually see weight reduction in the initial weeks of starting on the regular doses.
Studies suggests users may put most of the weight back on within a year of stopping the treatment, when their normal hunger come back.
To be carrying excess weight elevates your likelihood for developing medical conditions, such as diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight affects individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.
